FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
Read FDA announcement